GSA Capital Partners LLP bought a new position in Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,052 shares of the company's stock, valued at approximately $1,137,000.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. New Millennium Group LLC bought a new position in Cencora in the 2nd quarter valued at approximately $26,000. TCTC Holdings LLC bought a new position in shares of Cencora during the first quarter valued at $29,000. TFO Wealth Partners LLC purchased a new stake in shares of Cencora during the first quarter valued at $30,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora during the 2nd quarter valued at about $30,000. Finally, Concord Wealth Partners purchased a new stake in Cencora in the third quarter worth approximately $30,000. Institutional investors own 97.52% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. Wells Fargo & Company increased their price target on Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a report on Thursday, August 1st. StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Bank of America restated a "neutral" rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Evercore ISI increased their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Finally, Robert W. Baird boosted their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Cencora currently has an average rating of "Moderate Buy" and a consensus price target of $271.20.
Read Our Latest Report on Cencora
Cencora Price Performance
COR traded down $2.61 on Friday, hitting $240.24. 1,838,270 shares of the company's stock traded hands, compared to its average volume of 1,410,016. The company's 50 day simple moving average is $232.62 and its 200-day simple moving average is $231.08. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a one year low of $194.23 and a one year high of $251.56. The firm has a market cap of $47.34 billion, a price-to-earnings ratio of 31.99, a P/E/G ratio of 1.66 and a beta of 0.44.
Cencora Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.92%. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. Cencora's dividend payout ratio is presently 29.29%.
Insiders Place Their Bets
In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company's stock, valued at $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.80% of the stock is owned by insiders.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
